

Overview

For investors in pharmaceutical and biotech companies, rigorous monitoring of drug pipelines is essential. No milestone is more influential than the FDA approval decision date, frequently called the PDUFA date (from Prescription Drug User Fee Act).

This Revere Report features **companies with expected FDA approval decision dates in the next three months**. To provide further insights into **each drug candidate's likelihood of approval and competitive landscape**, the FDA Approval Decisions Report includes **key data based on Revere's patented classification system and proprietary pipeline database** – specifically, whether each drug candidate:

- utilizes a mechanism of action already approved by the FDA in other drugs
- faces two or fewer alternative drugs with the same mechanism of action for the same indication
- would be the first or second FDA approved drug for the company

Report Contents

1. March Approval Results/Updates
2. Companies with Expected PDUFA Dates In the Next Three Months
3. Expected PDUFA Dates by Sector
4. April Drug Candidates
5. May Drug Candidates
6. June Drug Candidates
7. Price and Financial Info

Copyright 2005 by Revere Data, LLC. All rights reserved.

Notes:

- a) Some expected PDUFA (Prescription Drug User Fee Act) dates are Revere estimates based on NDA (New Drug Approval) submission dates. Companies are not obligated to disclose NDA submission dates or PDUFA dates, and the FDA may change its approval decision date without prior notice.
- b) Drugs developed by private firms or by companies not traded publicly in the U.S. are excluded from this analysis.

Disclaimer:

Revere Data is an independent provider of investment research and information and does not offer broker / dealer, money management, hedge fund management, investment advisory, or investment banking services.

The information contained in this report is based on a limited analysis of qualitative, statistical, and financial data and should not be interpreted as recommendations based on a complete investment evaluation. The information is based on sources that Revere Data believes to be reliable, but no representation, express or implied, is made with respect to the accuracy, completeness, reliability, or timeliness. The information is subject to change without notice, and Revere Data does not accept responsibility to update it.

Revere Data does not accept responsibility or liability for any direct, indirect, special, consequential, or other losses or damages of any kind whatsoever arising out of access to, or use of, this report or any information contained in it.

Principals or employees of Revere Data may have a position in, and may from time to time purchase or sell, securities of any company discussed in this report.

For more information on Revere's independent research data and investment analytics, please click [here](#) or contact us as follows:

Revere Data, LLC | 2 Rector Street, Suite 900 | New York, NY 10006
866.REVERE9 (866.738.3739) | sales@reveredata.com | www.reveredata.com

1. March Approval Results/Updates

Company (Symbol)	Drug Candidate	Indication	Previous Expected PDUFA Date*	Primary Mechanism of Action (PMOA)	Approval Results/Update
Salix Pharmaceuticals Ltd (SLXP)	Osmoprep (formerly INKP-102)	Cleansing of Colon Prior to Colonoscopy	3/1/2006	Hyperosmotic Agents	Approved by FDA on 3/16/2006
Bristol Myers Squibb Co. (BMY) / ImClone Systems Incorporated (IMCL)	Erbix (Cetuximab)	Recurrent/ Metastatic Head & Neck Cancer; Locally Advanced Head & Neck Cancer in Combination with Radiation	3/2/2006	Monoclonal Antibodies	Approved by FDA on 3/1/2006
Amgen, Inc. (AMGN)	Aranesp (Darbepoetin Alfa)	Once Every 3 Weeks Dosing for the Treatment of Chemotherapy Induced Anemia	<i>3/6/2006</i>	Recombinant Human Erythropoietins	Approved by FDA on 3/27/2006
NPS Pharmaceuticals, Inc. (NPSP)	Preos (Human Parathyroid Hormone)	Reduce Fracture Rates in Women with Osteoporosis	3/10/2006	Parathyroid Hormone	Approvable Letter received on 3/10/2006
Cubist Pharmaceuticals (CBST)	Intravenous Cubicin (Daptomycin)	Bacteremia with Known or Suspected Endocarditis Caused by Staphylococcus aureus	3/24/2006	Lipopeptides	Approvable Letter received on 3/24/2006
Encysive Pharmaceuticals, Inc. (ENCY)	Thelin (Sitaxsentan)	Pulmonary Arterial Hypertension (PAH)	3/24/2006	Endothelin Receptor Antagonists	Approvable Letter received on 3/24/2006
Schering AG (SHR)	YAZ (Drospirenone/ Ethinyl Estradiol)	Premenstrual Dysphoric Disorder (PMDD)	<i>3/24/2006</i>	Estrogens/ Progestins	Approved by FDA on 3/16/2006
Santarus, Inc. (SNTS)	Zegerid Chewable Tablet (Omeprazole)	GERD, Erosive Esophagitis (EE), Duodenal Ulcer, Gastric Ulcers, Prevention of Upper GI Bleeding in Critically Ill Patients	3/27/2006	Proton Pump Inhibitors	Approved by FDA on 3/27/2006

Biogen Idec Inc (BIIB) / Elan Corporation, plc (ELN)	Tysabri (Natalizumab)	Relapsing Forms of Multiple Sclerosis	<i>3/27/2006</i>	Alpha 4 Integrin Inhibitors	PDUFA extended for 3 months to 6/28/2006
Wyeth (WYE)	Librel (Levonorgestrel/Ethinyl Estradiol)	Continuous Oral Contraceptive	<i>March 2006</i>	Estrogens/ Progestins	Result Pending
Bristol Myers Squibb Co. (BMY) / Mylan Laboratories Inc. (MYL) / Watson Pharmaceuticals, Inc. (WPI)	Emsam (Selegiline Transdermal System)	Major Depressive Disorder (MDD)	2/27/2006	Monoamine Oxidase (MAO) Inhibitors	Approved by FDA on 2/27/2006
Biogen Idec Inc. (BIIB) / Genentech, Inc. (DNA) / Roche Holding Ltd. (RHHBY)	Rituxan (Rituximab)	Moderate-to-Severe Rheumatoid Arthritis	<i>2/28/2006</i>	Monoclonal Antibodies	Approved by FDA on 2/28/2006
BioDelivery Sciences International, Inc. (BDSI) / Accentia Biopharmaceuticals, Inc. (ABPI)	Emezine (Buccal Prochlorperazine Maleate)	Severe Nausea/Vomiting	<i>2/28/2006</i>	Dopamine Receptor Blocking Agents	Non-Approvable Letter received on 2/28/2006
sanofi-aventis (SNY)	Taxotere (Docetaxel)	Advanced Gastric Cancer (Stomach Cancer)	<i>April 2006</i>	Antimicrotubule Agents	Approved by FDA on 3/22/2006

* Dates in **bold** indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. Dates in *italics* indicate Revere estimates based on NDA (New Drug Approval) submission dates.


























2. Companies with Expected PDUFA Dates in the Next Three Months

April	May	June
Alkermes, Inc. (ALKS)	Bristol Myers Squibb Co. (BMY)	Biogen Idec Inc (BIIB)
Cephalon, Inc. (CEPH) [3]	CollaGenex Pharmaceutical, Inc (CGPI)	BioMarin Pharmaceutical (BMRN)
Discovery Laboratories (DSCO)	DOV Pharmaceutical, Inc. (DOVP)	Bristol Myers Squibb Co. (BMY)
Genzyme Corporation (GENZ)	Johnson & Johnson (JNJ)	Celgene Corporation (CELG)
Noven Pharmaceuticals, Inc. (NOVN)	King Pharmaceuticals (KG)	Cellegy Pharmaceuticals, Inc. (CLGY)
Pfizer Inc. (PFE)	Merck & Co., Inc. (MRK)	Cephalon, Inc. (CEPH)
Salix Pharmaceuticals Ltd (SLXP)	MGi Pharma, Inc. (MOGN)	DOV Pharmaceutical, Inc (DOVP)
Shire plc (SHPGY)	Neurocrine Biosciences, Inc. (NBIX)	Elan Corporation, plc (ELN)
	Pfizer Inc. (PFE) [2]	Endo Pharmaceuticals (ENDP)
	sanofi-aventis (SNY) [2]	Genentech, Inc. (DNA)
	Shire plc (SHPGY)	GlaxoSmithKline plc (GSK) [2]
	SuperGen, Inc. (SUPG)	Johnson & Johnson (JNJ)
	Wyeth (WYE)	Merck & Co., Inc. (MRK)
		Neurocrine Biosciences, Inc. (NBIX)
		Novartis AG (NVS)
		Penwest Pharmaceuticals (PPCO)
		Pfizer Inc. (PFE)
		POZEN Inc. (POZN)
		Roche Holding Ltd. (RHHBY)
		sanofi-aventis (SNY) [2]
Total Companies = 8	Total Companies = 13	Total Companies = 20

Notes:

1. Some drug candidates are filed jointly by two companies.
2. Companies with multiple drug candidates in the same month are shown in **bold type** with the number of drug candidates in brackets [].
3. Click the company name to view all NDA (New Drug Approval) Filed drug candidates for the company in [Revere Research](#).

3. Expected PDUFA Dates by Sector*

April	May	June
*Healthcare  Biopharmaceuticals [8]  Digestive System/Surgery [1]  Endocrinology/Metabolism [2]  Neurology [3]  Respiratory System [1]  Toxicology [1]	*Healthcare  Biopharmaceuticals [11]  Cardiovascular System [1]  Dermatology [1]  Endocrinology/Metabolism [1]  Hematology [1]  Infectious Diseases [2]  Neurology [2]  Pain Management [1]  Toxicology [1]  Urology [1]	*Healthcare  Biopharmaceuticals [16]  Cardiovascular System [1]  Digestive System [1]  Infectious Diseases [3]  Neurology [3]  Oncology [3]  Ophthalmology [1]  Pain Management [3]  Respiratory System [1]
Total PDUFA Dates = 8	Total PDUFA Dates = 11	Total PDUFA Dates = 16

* Based on Revere's [proprietary classification system](#).

4. April Drug Candidates

Company (Symbol)	Drug Candidate	Indication	Expected PDUFA Date*	Primary Mechanism of Action (PMOA)	Proven PMOA?	If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication?	1st or 2nd FDA Approved Drug of the Company?
Discovery Laboratories (DSCO)	Surfaxin (Lucinactant)	Prevention of Respiratory Distress Syndrome (RDS) in Premature Infants	4/05/2006	Surfactants	Yes	No—Multiple	Yes
Alkermes, Inc. (ALKS) / Cephalon, Inc. (CEPH)	Medisorb Vivitrol (Naltrexone)	Alcohol Dependence	4/17/2006	Opioid Antagonists	Yes	Yes—ReVia (BRL)	Yes (ALKS) / No (CEPH)
Noven Pharmaceuticals, Inc. (NOVN) / Shire plc (SHPGY)	Daytrana (Methylphenidate)	Attention Deficit Hyperactivity Disorder (ADHD)	4/19/2006	Dopamine Receptor Blocking Agents	Yes	No—Multiple	No
Cephalon, Inc. (CEPH)	Nuvigil (Armodafinil)	Excessive Sleepiness Associated with Narcolepsy, Shift Work Sleep Disorder, and Obstructive Sleep Apnea/Hypopnea Syndrome	4/28/2006	Alpha Adrenergic Receptor Agonists	Yes	Yes—Only Drug Candidate with This PMOA for This Indication	No
Genzyme Corporation (GENZ)	Myozyme (Alpha-Glucosidase)	Pompe Disease	4/28/2006	Enzyme Replacement Therapy	Yes	Yes—Only Drug Candidate with This PMOA for This Indication	No

Cephalon, Inc. (CEPH)	Sparlon (Modafinil)	Attention Deficit Hyperactivity Disorder (ADHD) in Children and Adolescents Aged 6 to 17	<i>April 2006</i>	Alpha Adrenergic Receptor Agonists	Yes	Yes—SPD503/SPD465 (SHPGY)	No
Pfizer Inc. (PFE)	Genotropin (Recombinant Human Growth Hormone)	Short Stature and Growth Problems Associated with Turner's Syndrome	<i>April 2006</i>	Growth Hormones	Yes	No—Multiple	No
Salix Pharmaceuticals Ltd (SLXP)	NRL944	Bowel Cleansing Prior to Colonoscopy, Intestinal Surgery and Barium Enema X-Ray Examinations	<i>April 2006</i>	Hyperosmotic Agents	Yes	**Yes—Colyte (SWTZY), LoSoPrep/ LiquiPrep (EZEM)	No

* Dates in **bold** indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. Dates in *italics* indicate Revere estimates based on NDA (New Drug Approval) submission dates.

**SLXP's OsmoPrep and Visicol are also indicated for Cleansing of Colon Prior to Colonoscopy.

5. May Drug Candidates

Company (Symbol)	Drug Candidate	Indication	Expected PDUFA Date*	Primary Mechanism of Action (PMOA)	Proven PMOA?	If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication?	1st or 2nd FDA Approved Drug of the Company?
DOV Pharmaceutical, Inc. (DOVP) / Neurocrine Biosciences, Inc. (NBIX) / Pfizer Inc. (PFE)	Indiplon Immediate Release Capsule	Primary (Chronic) and Transient Insomnia	5/15/2006	Gamma-Aminobutyric Acid (GABA) Receptor Agonists	Yes	No—Multiple	Yes (DOVP) / Yes (NBIX) / No (PFE)
MGi Pharma, Inc. (MOGN) / SuperGen, Inc. (SUPG)	Dacogen (Decitabine)	Myelodysplastic Syndrome (MDS)	5/15/2006	Pyrimidine Analogs	Yes	Yes—Vidaza (PHRM)	No
Bristol Myers Squibb Co. (BMY) / sanofi-aventis (SNY)	Plavix (Clopidogrel Bisulfate)	Acute ST-Segment Elevation Myocardial Infarction	<i>5/18/2006</i>	Adenosine Diphosphate (ADP) Inhibitors	Yes	Yes—Only Drug Candidate with This PMOA for This Indication	No
King Pharmaceuticals (KG) / Wyeth (WYE)	Altace (Ramipril)	Delaying the Progression of Chronic Kidney Disease In Hypertensive, Non-Diabetic Patients	<i>5/22/2006</i>	Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)	Yes	Yes—Only Drug Candidate with This PMOA for This Indication	No
Merck & Co., Inc. (MRK)	Zostavax	Herpes Zoster (Shingles) Vaccine, Prevention of Postherpetic Neuralgia (PHN), Reduction of Acute and Chronic Shingles-Associated Pain in Adults	5/25/2006	Herpes Zoster (Shingles) Vaccines	No	Yes—Only Drug Candidate with This PMOA for This Indication	No

Shire plc (SHPGY)	Elaprase (Idursulfase)	Hunter Syndrome (Mucopolysaccharidosis II)	5/25/2006	Enzyme Replacement Therapy	Yes	Yes—Only Drug Candidate with This PMOA for This Indication	No
Sanofi-aventis (SNY)	Pentacel	Combination Vaccine for Diphtheria, Tetanus, Pertussis, Polio, Haemophilus influenzae type b (Hib) in Children	<i>5/25/2006</i>	Bacterial/Viral Vaccines	Yes	Yes—Infanrix HeXa-HepB-IPV/Hib (GSK)	No
Johnson & Johnson (JNJ)	ALZA lonsys (E-Trans Fentanyl)	Management of Acute Post-Operative Pain	<i>5/29/2006</i>	Opioids	Yes	No—Multiple	No
CollaGenex Pharmaceutical, Inc (CGPI)	Oracea (Doxycycline Hyclate Modified Release)	Rosacea	5/31/2006	Tetracyclines	Yes	Yes—Only Drug Candidate with This PMOA for This Indication	No
Pfizer Inc. (PFE)	Champix (Varenicline)	Smoking Cessation	<i>May 2006</i>	Nicotinic Receptor Agonists	Yes	No—Multiple	No
Novartis AG (NVS)	Exelon (Rivastigmine Tartrate)	Mild to Moderate Dementia Associated with Parkinson's Disease	<i>May 2006</i>	Acetylcholinesterase Inhibitors	Yes	**Yes—Only Drug Candidate with This PMOA for This Indication	No

* Dates in **bold** indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. Dates in *italics* indicate Revere estimates based on NDA (New Drug Approval) submission dates.

**Pfizer's Donepezil Hydrochloride is in Phase 3 trial for treating general Dementia, not specific to Parkinson's Disease.

6. June Drug Candidate

Company (Symbol)	Drug Candidate	Indication	Expected PDUFA Date*	Primary Mechanism of Action (PMOA)	Proven PMOA?	If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication?	1st or 2 nd FDA Approved Drug of the Company?
BioMarin Pharmaceutical (BMRN)	Orapred ODT (Prednisolone Sodium Phosphate)	Severe Asthma	6/1/2006	Steroidal Anti-Inflammatory Drugs (SAID)	Yes	No—Multiple	No
sanofi-aventis (SNY)	Multaq (Dronedarone)	Atrial Fibrillation	<i>June 2006</i>	Sodium Channel Blocking Agents/ Potassium Channel Blocking Agents	Yes	No-Multiple	No
Merck & Co., Inc. (MRK) / sanofi-aventis (SNY)	Gardasil	Human Papillomavirus (HPV) Vaccine, Cervical Cancer Vaccine	6/8/2006	Papillomavirus Vaccines	No	Yes—Cervarix (GSK)	No
GlaxoSmithKline plc (GSK) / POZEN Inc. (POZN)	Trexima (Naproxen/ Sumatriptan)	First-Line Therapy for Migraine Headaches	<i>6/8/2006</i>	Non-Steroidal Anti-Inflammatory Drugs (NSAID)/Selective Serotonin Receptor Agonists	No	Yes—Only Drug Candidate with This PMOA for This Indication	No (GSK) / Yes (POZN)

GlaxoSmithKline plc (GSK)	Hycamtin (Topotecan Hydrochloride)	Recurrent or Persistent Cervical Cancer Not Amenable to Curative Treatment with Surgery and/or Radiation Therapy	6/15/2006	Topoisomerase I Inhibitors	Yes	Yes—Only Drug Candidate with This PMOA for This Indication	No
Endo Pharmaceuticals (ENDP) / Penwest Pharmaceuticals (PPCO)	EN3202 (Oxymorphone Hydrochloride Extended-Release)	Moderate-to-Severe Pain	6/22/2006	Opioids	Yes	No-Multiple	No (ENDP) / Yes (PPCO)
Endo Pharmaceuticals (ENDP)	EN3203 (Oxymorphone Hydrochloride Immediate-Release)	Moderate-to-Severe Pain	6/22/2006	Opioids	Yes	No-Multiple	No
Schering-Plough Corp. (SGP)	Noxafil (Posaconazole)	Prophylaxis of Serious Invasive Fungal Infections in High Risk Patients	6/22/2006	Imidazoles	Yes	Yes—Nizoral (JNJ)	No
Johnson & Johnson (JNJ)	Tibotec TMC 114	Human Immunodeficiency Virus (HIV)	6/23/2006	Protease Inhibitors	Yes	No-Multiple	No
DOV Pharmaceutical, Inc. (DOVP) / Neurocrine Biosciences, Inc. (NBIX) / Pfizer, Inc. (PFE)	Indiplon Modified Release Tablet	Primary (Chronic) and Transient Insomnia	6/27/2006	Gamma-Aminobutyric Acid (GABA) Receptor Agonists	Yes	No-Multiple	Yes (DOVP) / Yes (NBIX) / No (PFE)
Biogen Idec Inc (BIIB) / Elan Corporation, plc (ELN)	Tysabri (Natalizumab)	Relapsing Forms of Multiple Sclerosis	6/28/2006	Alpha 4 Integrin Inhibitors	No	Yes—Only Drug Candidate with This PMOA for This Indication	No
Bristol Myers Squibb Co. (BMY)	Dasatinib (Src/Abl Kinase Inhibitor)	Chronic Myelogenous Leukemia (CML)	6/28/2006	Tyrosine Kinase Inhibitors	Yes	Yes—Gleevec/Glivec (NVS)	No
Celgene Corporation (CELG)	Revlimid (Lenalidomide)	Relapsed/Refractory Multiple Myeloma	6/30/2006	Immunomodulatory Agents	Yes	Yes—Only Drug Candidate with This PMOA for This Indication	No
Roche Holding Ltd. (RHHBY) / Novartis AG (NVS) / Genentech, Inc. (DNA)	Lucentis (Ranibizumab)	Wet Age-Related Macular Degeneration (AMD)	6/30/2006	Vascular Endothelial Growth Factor Inhibitors (VEGF)	Yes	Yes—Macugen (PFE, OSIP, NKTR, ENZN)	No
Cephalon, Inc. (CEPH)	Cima Labs OraVescent Fentanyl	Management of Breakthrough Pain in Patients with Cancer	6/30/2006	Opioids	Yes	No-Multiple	No

Cellegy Pharmaceuticals, Inc. (CLGY)	Cellegesic (Nitroglycerin)	Pain Associated with Anal Fissures/Treatment of Anal Fissures	6/30/2006	Vasodilatory Agents	Yes	Yes—Only Drug Candidate with This PMOA for This Indication	Yes
--------------------------------------	----------------------------	---	-----------	---------------------	-----	--	-----

* Dates in **bold** indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. Dates in *italics* indicate Revere estimates based on NDA (New Drug Approval) submission dates.

7. Price and Financial Info Data as of March 28, 2006

	Company (Symbol)	Last Price	Market Cap. (M)	30-Day Avg. Volume	Price/Book	Total Debt/Equity (MRQ)	Cash & Equivalents + Short-Term Investments (MRQ) (M)	1-Year Return	Relative Performance vs. Revere Biopharm Index	Institutional Holdings (Subscribers Only)	Options Available ?
April	Alkermes, Inc. (ALKS)	23.09	2,121	1,309,238	90.93	13.33	314	112.22%	89.63%	●	YES
	Cephalon, Inc. (CEPH)	59.82	3,591	4,550,195	5.64	2.77	484	26.95%	4.36%	●	YES
	Discovery Laboratories (DSCO)	7.68	413	554,148	11.51	0.30	50	31.73%	9.14%	●	YES
	Genzyme Corporation (GENZ)	65.75	17,081	1,974,508	3.11	0.16	486	13.77%	-8.82%	●	YES
	Noven Pharmaceuticals, Inc. (NOVN)	17.5	414	230,104	2.86	0.00	85	6.12%	-16.47%	●	YES
	Pfizer Inc. (PFE)	25.35	186,342	21,988,560	2.84	0.27	22,736	-3.35%	-25.94%	●	YES
	Salix Pharmaceuticals (SLXP)	16.49	765	897,773	3.20	0.00	68	-3.28%	-25.87%	●	YES
Shire plc (SHPGY)	46.23	7,702	662,906	4.21	0.00	663	43.13%	20.54%	●	YES	
May	Bristol Myers Squibb (BMY)	24.89	48,876	9,287,936	4.30	0.77	5,799	-0.64%	-23.23%	●	YES
	CollaGenex Pharmaceutical, (CGPI)	14.07	204	121,270	5.72	0.00	44	195.59%	195.59%	●	YES
	DOV Pharmaceutical (DOVP)	15.75	366	375,152	N/A	N/A	98	14.71%	14.71%	●	NO
	Johnson & Johnson (JNJ)	59.60	177,374	7,624,136	4.63	0.07	16,138	-12.80%	-12.80%	●	YES
	King Pharmaceuticals (KG)	17.25	4,176	3,028,254	2.12	0.17	525	100.58%	100.58%	●	YES
	Merck & Co., Inc. (MRK)	35.65	77,968	6,359,990	4.34	0.45	15,638	12.25%	12.25%	●	YES
	MGi Pharma, Inc. (MOGN)	17.85	1,393	850,112	12.82	2.42	129	-27.82%	-27.82%	●	YES
	Neurocrine Biosciences, Inc. (NBIX)	66.40	2,471	654,473	6.34	0.15	273	66.92%	66.92%	●	YES
	Novartis AG (NVS)	55.43	115,172	928,476	3.47	0.26	10,933	17.81%	17.81%	●	YES
Pfizer Inc. (PFE)	25.35	186,342	21,988,560	2.84	0.27	22,736	-3.35%	-3.35%	●	YES	

	sanofi-aventis (SNY)	45.58	121,712	1,503,200	2.29	0.00	N/A	6.64%	6.64%	●	YES
	Shire plc (SHPGY)	46.23	7,702	662,906	4.21	0.00	663	43.13%	43.13%	●	YES
	SuperGen, Inc. (SUPG)	5.34	276	421,744	4.31	0.00	48	17.62%	17.62%	●	YES
June	Biogen Idec Inc (BIIB)	45.86	15,780	4,471,272	2.24	0.01	851	20.37%	-2.22%	●	YES
	BioMarin Pharmaceutical (BMRN)	13.45	1,005	1,990,855	N/A	N/A	49	188.01%	165.42%	●	YES
	Bristol Myers Squibb Co. (BMY)	24.89	48,876	9,287,936	4.30	0.77	5,799	-0.64%	-23.23%	●	YES
	Celgene Corporation (CELG)	41.35	14,265	2,957,808	21.32	0.63	724	156.43%	133.84%	●	YES
	Cellegy Pharmaceuticals, Inc. (CLGY)	0.93	28	56,511	N/A	N/A	2	-55.71%	-78.30%	●	NO
	Cephalon, Inc. (CEPH)	59.82	3,591	4,550,195	5.64	2.77	484	26.95%	4.36%	●	YES
	Elan Corporation, plc (ELN)	15.75	366	375,152	N/A	N/A	98	14.71%	-7.88%	●	YES
	Endo Pharmaceuticals (ENDP)	14.10	6,046	12,378,596	357.89	119.36	1,090	93.42%	70.83%	●	YES
	Genentech, Inc. (DNA)	32.03	4,258	1,193,310	5.01	0.00	501	48.01%	25.42%	●	YES
	GlaxoSmithKline plc (GSK)	83.65	88,152	3,271,240	11.51	0.28	2,365	47.01%	24.42%	●	YES
	Johnson & Johnson (JNJ)	52.65	153,200	1,210,005	11.85	0.89	9,149	14.63%	-7.96%	●	YES
	Merck & Co., Inc. (MRK)	59.60	177,374	7,624,136	4.63	0.07	16,138	-12.80%	-35.39%	●	YES
	Neurocrine Biosciences, Inc. (NBIX)	35.65	77,968	6,359,990	4.34	0.45	15,638	12.25%	-10.34%	●	YES
	Novartis AG (NVS)	55.43	115,172	928,476	3.47	0.26	10,933	17.81%	-4.78%	●	YES
	Penwest Pharmaceuticals (PPCO)	20.31	444	221,331	N/A	N/A	N/A	65.93%	43.34%	●	YES
	Pfizer Inc.	25.35	186,342	21,988,560	2.84	0.27	22,736	-3.35%	-25.94%	●	YES
POZEN Inc. (POZN)	16.99	495	224,784	13.35	0.00	46	240.48%	217.89%	●	YES	

Roche Holding Ltd. (RHHBY)	74.50	128,522	N/A	4.74	0.28	16,265	39.38%	16.79%	●	NO
sanofi-aventis (SNY)	45.58	121,712	1,503,200	2.29	N/A	N/A	6.64%	-15.95%	●	YES
Schering-Plough Corp. (SGP)	18.91	28,004	6,218,168	4.69	0.50	5,585	4.36%	-18.23%	●	YES